PRISCOLINE Drug Patent Profile
✉ Email this page to a colleague
When do Priscoline patents expire, and what generic alternatives are available?
Priscoline is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in PRISCOLINE is tolazoline hydrochloride. There is one drug master file entry for this compound. Additional details are available on the tolazoline hydrochloride profile page.
Summary for PRISCOLINE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 88 |
Patent Applications: | 3,517 |
Formulation / Manufacturing: | see details |
DailyMed Link: | PRISCOLINE at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for PRISCOLINE
US Patents and Regulatory Information for PRISCOLINE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | PRISCOLINE | tolazoline hydrochloride | INJECTABLE;INJECTION | 006403-005 | Feb 22, 1985 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |